CANADIAN ADULTS 50-64 YEARS OF AGE CONTRIBUTE SUBSTANTIALLY TO THE CASES OF INVASIVE PNEUMOCOCCAL DISEASE (IPD) POTENTIALLY PREVENTABLE BY THE 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE (ID 1230)

Session Name
Vaccines - Impact of Vaccine programs and Serotype Replacement
Presenter
  • Ana Gabriela Grajales, Canada
Authors
  • Ana Gabriela Grajales, Canada
  • Stephane Dion, Canada
  • Maria Major, Canada
  • Rajeev Nepal, Canada
  • Jose A. Suaya, United States of America
  • Alejandro Cane, Argentina
  • Jelena Vojicic, Canada

Abstract

Background

In Canada, age-based recommendation for adult pneumococcal vaccination starts at 65 years (routine for PPV23, on an individual basis for PCV13). Recent literature reports large additional pneumococcal pneumonia and non-pneumonia IPD burden in Canadian adults aged 50-64 years.

Methods

Case counts of IPD by serotype and age group were obtained from published annual National Microbiology Laboratory (NML) reports of passive laboratory-based surveillance. We calculated the proportion of all IPD cases occurring in adults 50-64, ≥65, and ≥50 years of age and trends in the proportion of PCV13-type IPD in these age groups, for 2010-2017.

Results

Between 2010 and 2017, adults aged 50-64 and ≥65 contributed 27% and 38% of 21, 610 reported IPD cases, respectively. The proportion of PCV13-type IPD declined from 52% to 34% in 50-64 cohort, and 50% to 23% in ≥65 cohort, showing a plateau since 2014 in all three age groups (Figure 1).isppd 50+.png

Conclusions

Adults ≥65 years contributed 38%, and those 50-64 years an incremental 27% of all IPD in Canada over the study period. In 2017, 23% and 34% of IPD in these two cohorts, respectively, was of PCV13-type. These findings support the rationale for intensified PCV13 immunization efforts in both age groups.

Hide